<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pregnancy in women with pre-existing chronic liver disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pregnancy in women with pre-existing chronic liver disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pregnancy in women with pre-existing chronic liver disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nancy Reau, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard H Lee, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sanjiv Chopra, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles J Lockwood, MD, MHCM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 09, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Liver disease in pregnant women can be seen in three general settings:</p><p class="bulletIndent1"><span class="glyph">●</span>The patient has liver disease induced by pregnancy, such as:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hyperemesis gravidarum (see  <a class="medical medical_review" href="/d/html/6792.html" rel="external">"Nausea and vomiting of pregnancy: Clinical findings and evaluation"</a> and  <a class="medical medical_review" href="/d/html/6811.html" rel="external">"Nausea and vomiting of pregnancy: Treatment and outcome"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Preeclampsia or the HELLP syndrome (hemolysis, elevated liver tests, and low platelets) (see  <a class="medical medical_review" href="/d/html/6814.html" rel="external">"Preeclampsia: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/6778.html" rel="external">"HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets)"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Intrahepatic cholestasis of pregnancy (see  <a class="medical medical_review" href="/d/html/3560.html" rel="external">"Intrahepatic cholestasis of pregnancy"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Acute fatty liver of pregnancy (see  <a class="medical medical_review" href="/d/html/3619.html" rel="external">"Acute fatty liver of pregnancy"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient has developed a new liver disease during pregnancy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient has pre-existing chronic liver disease</p><p></p><p>In order to avoid unintended pregnancy, patients with chronic liver disease should be counseled about contraceptive options, and the method of contraception provided must take the specific liver disease into account. Furthermore, patients contemplating pregnancy should have preconception counseling and disease-specific risk evaluation. (See  <a class="medical medical_review" href="/d/html/448.html" rel="external">"The preconception office visit"</a>.) </p><p>When a woman with chronic liver disease becomes pregnant, two separate issues arise [<a href="#rid1">1,2</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>What will be the effect of the liver disease or its treatment on the pregnancy and fetus, and </p><p class="bulletIndent1"><span class="glyph">●</span>How will pregnancy affect the health of the patient</p><p></p><p>This topic will review pregnancy in women with pre-existing chronic liver disease, including the effects on the fetus and on the patient. Pregnancy in women with chronic hepatitis B virus infection, the development of liver disease brought on by pregnancy, and the development of new (not pregnancy-related) liver disease during pregnancy are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/83476.html" rel="external">"Hepatitis B and pregnancy"</a> and  <a class="medical medical_review" href="/d/html/3563.html" rel="external">"Approach to evaluating pregnant patients with elevated liver biochemical and function tests"</a> and  <a class="medical medical_review" href="/d/html/3564.html" rel="external">"Overview of coincident acute hepatobiliary disease in pregnant women"</a>.)</p><p class="headingAnchor" id="H3695323480"><span class="h1">CONTRACEPTION</span></p><p class="headingAnchor" id="H781302804"><span class="h2">Contraceptive need</span><span class="headingEndMark"> — </span>Although patients with decompensated cirrhosis generally have decreased fertility, pregnancy is still possible [<a href="#rid1">1</a>]. While those with chronic liver disease without advanced fibrosis or compensated cirrhosis do not have diminished fertility, such patients may be at risk for complications. Women with chronic medical conditions are less likely to use highly effective contraception, and many pregnancies in women with cirrhosis are unplanned [<a href="#rid3">3,4</a>]. Thus, family planning and contraceptive needs are discussed with all patients of reproductive potential, including transgender and gender nonconforming patients. Further, patients with liver disease may ovulate irregularly or be intermittently anovulatory, which makes fertility difficult to assess [<a href="#rid5">5</a>]. </p><p class="headingAnchor" id="H4010925480"><span class="h2">Approach to contraceptive selection</span><span class="headingEndMark"> — </span>Information to guide the selection of contraception in women with medical disorders is available through the World Health Organization (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fpublications%2Fi%2Fitem%2F9789241549158&amp;token=mr3MkQMxxRm373pPGLTYB%2B8L7rJeOJtqYOfpSLq18h7bLDDnWC3XicBcpsIGU3t1%2BeMBqFM7dNdQ9NPFnY3uWg%3D%3D&amp;TOPIC_ID=3561" target="_blank">WHO Medical Eligibility Criteria</a>), the United States Centers for Disease Control (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fmmwr%2Fmec%2Fsummary.html&amp;token=gn9CxBU9SK4%2Bjug8DleFYAmCahKbgv18S9Zgv5fBNxTGoMdTGRC8XnfLV%2BmDF%2FKgq%2FUbcwPNhHygS%2BUPWWe15o2kSqIPMCtrmL2KJwaUlwQ%3D&amp;TOPIC_ID=3561" target="_blank">United States Medical Eligibility Criteria for Contraceptive Use</a>), and, in some cases, country-specific medical eligibility criteria. While the guidelines are generally similar, clinicians should use the one that best matches their population. When discussing contraceptive options with a patient who has chronic liver disease, the risks and side effects of the methods below must also be balanced against the risks of pregnancy, should it occur. The American Association for the Study of Liver Disease (AASLD) has developed practice guidance addressing reproductive health and liver disease to assist clinicians in managing this population [<a href="#rid6">6</a>]. In addition, general information on counseling women about contraceptive selection is available elsewhere. (See  <a class="medical medical_review" href="/d/html/5459.html" rel="external">"Contraception: Counseling and selection"</a>.)</p><p>Choice of the specific hormonal contraceptive method is guided by patient preferences around dosing schedule, mode of drug delivery, noncontraceptive benefits (eg, menstrual cycle regulation), and side effects. </p><p>While the patient ultimately selects the contraceptive method, the following outlines an approach to thinking about contraception in patients with chronic liver disease:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients who desire the most effective contraception or durable contraception, we discuss long-acting reversible contraceptives (LARCs), including the <a class="drug drug_general" data-topicid="93719" href="/d/drug information/93719.html" rel="external">copper intrauterine device</a> (IUD), levonorgestrel-releasing IUDs, and the <a class="drug drug_general" data-topicid="8870" href="/d/drug information/8870.html" rel="external">etonogestrel implant</a>  (<a class="graphic graphic_figure graphicRef119765" href="/d/graphic/119765.html" rel="external">figure 1</a>). These methods require minimal user action, have failure rates of less than 1 percent, have high continuation rates, and last from 3 to 12 years, depending on the device. Patients with normal liver function can use any of the LARC methods without restriction, including liver transplant recipients [<a href="#rid7">7,8</a>]. However, clinicians should be aware that the manufacturer's inserts for all levonorgestrel-releasing IUDs list acute liver disease or tumor as contraindications to use, but supporting evidence is not provided [<a href="#rid9">9-12</a>]. Both the levonorgestrel-releasing IUDs and the etonogestrel implant can reduce menstrual volume, which can be helpful in women with heavy menstrual bleeding. The copper IUD contains no hormones and thus can also be used by patients with severe liver disease, including decompensated cirrhosis, whereas the <a class="drug drug_general" data-topicid="104541" href="/d/drug information/104541.html" rel="external">levonorgestrel IUDs</a> and etonogestrel implant are avoided in patients with severe disease, Budd-Chiari syndrome, hepatocellular adenomas, and transplant recipients with graft failure [<a href="#rid6">6-8</a>]. However, as the copper IUD can also increase menstrual volume, we prefer to avoid it in patients with thrombocytopenia or heavy menstrual bleeding. The copper IUD is not used in patients with Wilson disease [<a href="#rid13">13</a>]. </p><p></p><p class="bulletIndent1">Detailed descriptions of the IUDs and implant are presented separately.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/116579.html" rel="external">"Intrauterine contraception: Background and device types"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/5419.html" rel="external">"Intrauterine contraception: Candidates and device selection"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/3266.html" rel="external">"Contraception: Etonogestrel implant"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who do not find LARC methods acceptable or who desire contraception for only a short timeframe, and who have normal hepatic function, we discuss short-acting hormonal contraception. These methods include combined estrogen-progestin products (oral pills, transdermal patch, and vaginal rings) and progestin-only methods (depot <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> injections and progestin-only oral pills). These methods are highly effective when used correctly and consistently, although they are less effective than LARC methods  (<a class="graphic graphic_figure graphicRef119765" href="/d/graphic/119765.html" rel="external">figure 1</a>). Although estrogens and progestins are metabolized by the liver, use of these products in patients with chronic liver disease has not been associated with worsening of the underlying disease or supratherapeutic levels of hormones [<a href="#rid14">14</a>]. However, these products are not advised for patients with decompensated cirrhosis, and initiation of estrogen-containing contraception is avoided in patients with increased risk of thromboembolism [<a href="#rid7">7,8,14</a>]. Women with hepatocellular adenoma (HCA) are cautioned about the use of estrogen-containing contraception, and this is discussed separately [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/d/html/3590.html" rel="external">"Hepatocellular adenoma"</a>.)</p><p></p><p class="bulletIndent1">Detailed descriptions of the hormone-containing short-acting contraceptives are presented in other topics.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/7398.html" rel="external">"Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/16682.html" rel="external">"Contraception: Hormonal contraceptive vaginal rings"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/5425.html" rel="external">"Contraception: Transdermal contraceptive patches"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/118540.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/5468.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Formulations, patient selection and drug administration"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/5461.html" rel="external">"Contraception: Progestin-only pills (POPs)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients at risk of sexually transmitted infection are advised about consistent condom use (male or female) even if other contraceptive methods are being used. (See  <a class="medical medical_review" href="/d/html/5463.html" rel="external">"External (formerly male) condoms"</a> and  <a class="medical medical_review" href="/d/html/5471.html" rel="external">"Internal (formerly female) condoms"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">CIRRHOSIS AND PORTAL HYPERTENSION</span><span class="headingEndMark"> — </span>Management of pregnant women with cirrhosis and portal hypertension involves a multidisciplinary team (maternal-fetal medicine, hepatology). Preconception counseling is advised for all women with cirrhosis who are contemplating pregnancy. Assisted reproduction in women with cirrhosis is not contraindicated, but Child-Pugh class B or C cirrhosis has been associated with higher risk of complications. (See  <a class="medical medical_review" href="/d/html/1263.html" rel="external">"Cirrhosis in adults: Overview of complications, general management, and prognosis", section on 'Child-Pugh classification'</a> and  <a class="medical medical_review" href="/d/html/7404.html" rel="external">"In vitro fertilization: Overview of clinical issues and questions"</a>.)</p><p>While pregnancy is generally uncommon in women with cirrhosis, pregnancy rates in such patients have been increasing [<a href="#rid16">16-18</a>]. In a database study including 339 pregnant women with cirrhosis who were admitted to the hospital, the mean number of deliveries increased annually from 68 (1993 to 1999) to 106 (2000 to 2005) [<a href="#rid17">17</a>]. In a cohort study including 2022 women with cirrhosis, the incidence of childbirth increased from 2.0 to 14.9 births per 100,000 person-years from the year 2000 to 2016 [<a href="#rid16">16</a>]. This trend is expected to continue with the increasing incidence of cirrhosis in women of childbearing age in the North America and Europe [<a href="#rid18">18,19</a>]. </p><p class="headingAnchor" id="H3981014451"><span class="h2">Maternal complications</span><span class="headingEndMark"> — </span>Maternal complications in pregnant women with cirrhosis include liver-related events and pregnancy-related events (see <a class="local">'Pregnancy outcomes'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy related complications – Pregnancy in women with cirrhosis has been associated with higher risk of pregnancy-related complications. In a cohort study of 2022 pregnant women with compensated cirrhosis (median maternal age at conception: 31 years), the most common etiology of cirrhosis was nonalcohol-associated fatty liver disease (NAFLD), and women with NAFLD were more likely to have baseline metabolic complications (pre-pregnancy diabetes, hypertension, obesity, dyslipidemia). Women with compensated cirrhosis were more likely to have complications such as hypertension, intrahepatic cholestasis of pregnancy (ICP), antepartum and postpartum hemorrhage, preterm birth, and puerperal infections compared with women in the general population [<a href="#rid16">16</a>]. For example, after adjusting for demographic and metabolic factors, cirrhosis was associated with a higher risk of intrahepatic cholestasis of pregnancy (ICP) (risk ratio [RR] 10.64, 95% CI 7.49-15.12). (See  <a class="medical medical_review" href="/d/html/3560.html" rel="external">"Intrahepatic cholestasis of pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Liver related complications – Although women with cirrhosis can sustain pregnancy without worsening of hepatic function [<a href="#rid20">20</a>], some women develop liver-related complications, with ascites reported in 10 to 25 percent and variceal bleeding in 7 to 42 percent of women [<a href="#rid4">4,20-22</a>]. In a study of 29 women and a total of 62 pregnancies, liver-related complications occurred in 10 percent of patients and were associated with higher Model for End-stage Liver Disease (MELD) scores at the time of conception [<a href="#rid4">4</a>]. A preconception MELD score of ≥10 was a risk factor for hepatic decompensation during pregnancy. The MELD scoring system is a prognostic model for estimating disease severity and survival in patients with chronic liver disease. (See  <a class="medical medical_review" href="/d/html/1241.html" rel="external">"Model for End-stage Liver Disease (MELD)"</a>.) </p><p></p><p class="bulletIndent1">In a cohort study including 2022 pregnant women with compensated cirrhosis, 34 patients (2 percent) experienced hepatic decompensation, and the majority of decompensating events occurred prior to delivery [<a href="#rid16">16</a>]. Variceal hemorrhage was the most commonly reported event (21 women [62 percent]), followed by ascites, hepatic failure, hepatic encephalopathy and hepatorenal syndrome. Six women (0.3 percent) died. This has been a significant improvement over historical cohorts where mortality of up to 10 percent was reported, possibly reflecting improvements in recognizing and managing complications of cirrhosis. However, early studies generally captured data from referral centers which may have included more women with decompensated liver disease. </p><p></p><p class="bulletIndent1">As the increase in total blood volume associated with pregnancy may worsen portal hypertension, rates of variceal hemorrhage are higher after the second trimester. Compression from the gravid uterus combined with repeated Valsalva maneuvers further increase bleeding risk during the second stage of labor [<a href="#rid4">4,23-26</a>]. Variceal bleeding during pregnancy should be managed similarly to nonpregnant patients, and management of variceal bleeding including pharmacologic and endoscopic therapy is discussed separately. (See  <a class="medical medical_review" href="/d/html/1254.html" rel="external">"Overview of the management of patients with variceal bleeding"</a> and  <a class="medical medical_review" href="/d/html/1260.html" rel="external">"Methods to achieve hemostasis in patients with acute variceal hemorrhage"</a>.).</p><p></p><p class="bulletIndent1">Measures to control increased pressure transmitted to collateral vessels during labor can be helpful. One method to avoid straining during delivery is to place an epidural early in labor and allow the infant to descend with uterine contractions alone. Delivery is then assisted using low forceps or vacuum extraction. (See  <a class="medical medical_review" href="/d/html/4474.html" rel="external">"Assisted (operative) vaginal birth"</a>.)</p><p></p><p class="bulletIndent1">Spontaneous rupture of a splenic artery aneurysm is a rare complication of pregnancy in women with portal hypertension and is also a known complication of pregnancy in patients without portal hypertension [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/d/html/4807.html" rel="external">"Approach to acute abdominal/pelvic pain in pregnant and postpartum patients", section on 'Visceral artery aneurysm rupture'</a> and  <a class="medical medical_review" href="/d/html/7134.html" rel="external">"Splenomegaly and other splenic disorders in adults", section on 'Splenic artery aneurysm'</a>.)</p><p></p><p class="headingAnchor" id="H4142672751"><span class="h2">Assessing risk for variceal bleeding</span><span class="headingEndMark"> — </span>The bleeding risk for women with portal hypertension is ideally evaluated prior to conception [<a href="#rid28">28</a>]. Women with cirrhosis or portal hypertension who desire pregnancy should have an upper endoscopy to look for varices before pregnancy. If present, patients should be informed of the increased risk of gastrointestinal hemorrhage with pregnancy. If not previously done, upper endoscopy should be performed in the second trimester. (See  <a class="medical medical_review" href="/d/html/1244.html" rel="external">"Pathogenesis of variceal bleeding in patients with cirrhosis"</a>.)</p><p>Patients at high risk for variceal hemorrhage should receive primary prophylaxis with nonselective beta blockers or undergo endoscopic variceal ligation. <a class="drug drug_general" data-topicid="9208" href="/d/drug information/9208.html" rel="external">Carvedilol</a> is a nonselective betablocker with mild anti-alpha 1 adrenergic activity that results in greater reduction in portal pressure [<a href="#rid29">29</a>]. Selecting a preventive strategy, including contraindications to beta blocker use, are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1245.html" rel="external">"Primary prevention of bleeding from esophageal varices in patients with cirrhosis"</a>.) </p><p>Prophylaxis with beta blockers should be continued during pregnancy, but newborns should be monitored during the first days of life because of risks of hypoglycemia and bradycardia. Both salvage and preventive transjugular intrahepatic portosystemic shunt (TIPS) placement has been reported during pregnancy [<a href="#rid30">30</a>]. In addition, all patients should be monitored by a maternal fetal medicine specialist. (See  <a class="medical medical_review" href="/d/html/1265.html" rel="external">"Overview of transjugular intrahepatic portosystemic shunts (TIPS)"</a>.)</p><p class="headingAnchor" id="H2537682985"><span class="h2">Pregnancy outcomes</span><span class="headingEndMark"> — </span>Data have suggested that cirrhosis was associated with higher rates of adverse maternal and infant outcomes [<a href="#rid4">4,17,20,31,32</a>]. The incidence of stillbirths and premature delivery was increased in women with cirrhosis or portal hypertension [<a href="#rid4">4,20,31</a>]. In a retrospective cohort study of 31 women with cirrhosis, the rate of at least one obstetrical complication (ie, preterm delivery, preeclampsia, placental abruption, small for gestational age, and fetal or neonatal death) was higher in women with cirrhosis compared with a control group without cirrhosis, matched for maternal age, parity, and body mass index (61 versus 12 percent, odds ratio [OR] 11.5, 95% CI 4.7-28.4) [<a href="#rid31">31</a>]. There were three cases of fetal or neonatal deaths in women with cirrhosis compared with none in the control group [<a href="#rid31">31</a>]. In a study of 29 women with a total of 62 pregnancies, the live birth rate was 58 percent, with a median gestational age of 36 weeks. Higher MELD/MELD-Na scores and higher Child-Pugh scores were associated with preterm delivery [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/1241.html" rel="external">"Model for End-stage Liver Disease (MELD)"</a> and  <a class="medical medical_review" href="/d/html/1263.html" rel="external">"Cirrhosis in adults: Overview of complications, general management, and prognosis", section on 'Child-Pugh classification'</a>.)</p><p>Spontaneous fetal loss occurred in 26 percent of pregnancies (19 percent were miscarriages prior to 20 weeks gestation, and 6 percent were stillbirths after 20 weeks gestation). It should be noted that published reports may be biased toward complications, leading to an overestimation of the risk. Although maternal and infant outcomes were substantially better in a subsequent cohort study including 2022 pregnant women with compensated cirrhosis, infant mortality was higher for mothers with cirrhosis compared with the general population (0.7 versus 0.3 percent) [<a href="#rid16">16</a>]. Infants born to mothers with compensated cirrhosis were more likely to be large for gestational age. In addition, the risk of stillbirth, respiratory distress, or death within one year of birth was higher in women with cirrhosis compared with the general population. </p><p class="headingAnchor" id="H146901940"><span class="h1">CHRONIC VIRAL HEPATITIS</span></p><p class="headingAnchor" id="H146902162"><span class="h2">Chronic hepatitis B virus</span><span class="headingEndMark"> — </span>Chronic hepatitis B virus infection in pregnancy is discussed separately. (See  <a class="medical medical_review" href="/d/html/83476.html" rel="external">"Hepatitis B and pregnancy"</a>.) </p><p class="headingAnchor" id="H146902198"><span class="h2">Chronic hepatitis C virus</span><span class="headingEndMark"> — </span>Hepatitis C virus (HCV) infection rates in women of reproductive age have been increasing [<a href="#rid33">33</a>]. We agree with recommendations from the CDC and other professional societies to screen pregnant individuals for HCV during each pregnancy [<a href="#rid34">34-37</a>]. (See  <a class="medical medical_review" href="/d/html/89950.html" rel="external">"Screening and diagnosis of chronic hepatitis C virus infection"</a>.)</p><p>Most women chronically infected with HCV will have an uneventful pregnancy without worsening of liver disease or other adverse effects on the mother or fetus [<a href="#rid38">38</a>]. However, some studies evaluating the impact of chronic HCV on hepatic, maternal, and fetal outcomes have suggested potential harms. In a population-based cohort study, infants of HCV-positive mothers were more likely to be of low birth weight (odds ratio [OR] 2.2, 95% CI 1.2-3.8), small for gestational age (OR 1.5, 95% CI 1.0-2.1), need assisted ventilation (OR 2.4, 95% CI 1.4-3.9), or require neonatal intensive care (OR 2.9, 95% CI 1.9-4.6) [<a href="#rid39">39</a>]. There were nonsignificant trends for low APGAR scores (OR 1.5, 95% CI 0.9-2.5), prematurity (OR 1.5, 95% CI 1.0-2.4), and neonatal jaundice (OR 1.3, 95% CI 0.8-1.9) being associated with HCV. </p><p>In addition, studies have confirmed that maternal HCV infection is associated with an increased risk for intrahepatic cholestasis of pregnancy [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/d/html/3560.html" rel="external">"Intrahepatic cholestasis of pregnancy"</a>.) </p><p>An improvement in serum aminotransferase concentrations in pregnant women with chronic HCV has been observed in some reports, possibly related to the immune suppressive state during pregnancy [<a href="#rid41">41-43</a>]. Aminotransferase levels typically return to baseline postpartum. </p><p>Studies have had conflicting results regarding the effect of pregnancy on histologic progression in women with chronic HCV, but most suggest minimal impact. Still, at least one study suggested that pregnancy may be associated with worsening histology on liver biopsy [<a href="#rid44">44</a>]. Twelve HCV-positive women who underwent liver biopsies before and after pregnancy were compared with 12 matched HCV positive controls who underwent paired liver biopsies but did not have an intervening pregnancy. Women who had been pregnant were more likely to have worsening of the necroinflammatory and fibrosis scores on liver biopsy compared with women who had not been pregnant. By contrast, another study found that pregnancy was associated with improvement in long-term progression of fibrosis [<a href="#rid45">45</a>].</p><p>Transmission of HCV from the mother to the newborn can occur, with estimated rates of transmission between 3 and 10 percent [<a href="#rid40">40,46</a>]. Some studies have suggested that viral load was associated with increased risk of mother to child transmission [<a href="#rid40">40</a>]. Issues surrounding vertical transmission of HCV including risk factors, management of HCV-infected women, labor and delivery management, neonatal diagnosis, and breastfeeding are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3637.html" rel="external">"Vertical transmission of hepatitis C virus"</a>.)</p><p>HCV exposure with resolved infection does not appear to impact pregnancy outcomes [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H334873429"><span class="h2">Hepatitis E</span><span class="headingEndMark"> — </span>Issues related to hepatitis E in a woman who is pregnant are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3677.html" rel="external">"Hepatitis E virus infection", section on 'Pregnant women'</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">NONVIRAL LIVER DISEASES</span></p><p class="headingAnchor" id="H8"><span class="h2">Autoimmune hepatitis</span><span class="headingEndMark"> — </span>Pregnancy in women with autoimmune hepatitis is discussed separately [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/d/html/3659.html" rel="external">"Management of autoimmune hepatitis", section on 'Pregnancy'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Primary biliary cholangitis</span><span class="headingEndMark"> — </span>The course of primary biliary cholangitis (PBC) during pregnancy is uncertain. Case reports have demonstrated that the disease may remain quiescent, improve, or worsen during pregnancy [<a href="#rid48">48-50</a>]. Treatment of PBC most commonly involves <a class="drug drug_general" data-topicid="10033" href="/d/drug information/10033.html" rel="external">ursodeoxycholic acid</a> (UDCA), which studies have suggested is safe during pregnancy [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/d/html/3560.html" rel="external">"Intrahepatic cholestasis of pregnancy", section on 'Ursodeoxycholic acid'</a>.) <a class="drug drug_general" data-topicid="108368" href="/d/drug information/108368.html" rel="external">Obeticholic acid</a> and fibrates are not used during pregnancy due to lack of safety data [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/d/html/3623.html" rel="external">"Overview of the management of primary biliary cholangitis"</a>.) </p><p>Recommendations for management of PBC during pregnancy have been proposed in practice guidance issued by the American Association for the Study of Liver Diseases [<a href="#rid52">52</a>]. The guidance statement advises screening for varices in the second trimester and treating with nonselective beta blockers if indicated. </p><p class="headingAnchor" id="H4981174"><span class="h2">Primary sclerosing cholangitis</span><span class="headingEndMark"> — </span>Data are limited with regard to pregnancy in women with primary sclerosing cholangitis (PSC). One series from Germany compared 229 patients with PSC with 569 healthy controls [<a href="#rid53">53</a>]. Patients with PSC did not differ significantly from healthy controls with regard to the number who had children or the mean number of children per person (53 versus 53 percent and 1.06 versus 1.01, respectively). In a population-based study from Sweden, 229 singleton births from women with PSC were compared with over two million births from mothers without PSC [<a href="#rid54">54</a>]. PSC was associated with increases in the risks of preterm birth and need for cesarean delivery (adjusted prevalence odds ratios [OR] of 3.6 and 2.2, respectively) independent of coexisting inflammatory bowel disease, but it was not associated with small for gestational age, congenital anomalies, stillbirth, or neonatal death. According to the results of this study, pregnancy should not be discouraged in women with PSC [<a href="#rid54">54</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Wilson disease</span><span class="headingEndMark"> — </span>Women who have been anovulatory because of Wilson disease can regain their fertility when treated, often quite promptly. Maintaining therapy during pregnancy is important because interrupting therapy has been associated with hemolytic episodes with hepatic insufficiency and maternal death. The treatment of pregnant women with Wilson disease is discussed elsewhere [<a href="#rid55">55</a>]. (See  <a class="medical medical_review" href="/d/html/3591.html" rel="external">"Wilson disease: Management"</a>.) </p><p>Patients with Wilson disease and cirrhosis may be at increased risk for obstetrical complications such as intrauterine growth restriction and preeclampsia, and they should be referred to a maternal-fetal medicine specialist. </p><p class="headingAnchor" id="H11"><span class="h2">Hepatocellular adenoma</span><span class="headingEndMark"> — </span>Hepatocellular adenoma (HCA) has been associated with estrogen use (eg, oral contraceptives), and HCA may grow during pregnancy [<a href="#rid56">56</a>]. For pregnant women with HCA, surveillance imaging is performed, and if the lesion becomes symptomatic or large, patients are evaluated for intervention (eg, surgical resection) [<a href="#rid57">57</a>]. Management of patients with HCA is discussed separately. (See  <a class="medical medical_review" href="/d/html/3590.html" rel="external">"Hepatocellular adenoma"</a>.)</p><p class="headingAnchor" id="H1803414802"><span class="h2">Other solid liver lesions</span><span class="headingEndMark"> — </span>Women with asymptomatic focal nodular hyperplasia (FNH) do not require monitoring during pregnancy because this liver lesion is not hormone sensitive [<a href="#rid58">58</a>]. (See  <a class="medical medical_review" href="/d/html/3577.html" rel="external">"Focal nodular hyperplasia"</a>.)</p><p>Women with hepatic hemangioma who are asymptomatic do not routinely require monitoring during pregnancy, and this is discussed separately. (See  <a class="medical medical_review" href="/d/html/3594.html" rel="external">"Hepatic hemangioma", section on 'Pregnancy'</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Familial hyperbilirubinemia</span><span class="headingEndMark"> — </span>The unconjugated hyperbilirubinemia of Gilbert syndrome is not exacerbated by pregnancy [<a href="#rid59">59</a>]. By comparison, the conjugated hyperbilirubinemia of Dubin-Johnson syndrome may worsen during gestation but returns to baseline levels after delivery [<a href="#rid60">60</a>]. (See  <a class="medical medical_review" href="/d/html/3578.html" rel="external">"Gilbert syndrome"</a> and  <a class="medical medical_review" href="/d/html/3584.html" rel="external">"Inherited disorders associated with conjugated hyperbilirubinemia", section on 'Dubin-Johnson syndrome'</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Familial intrahepatic cholestatic syndromes</span><span class="headingEndMark"> — </span>Examples of these rare diseases include Alagille syndrome and Byler syndrome (progressive familial intrahepatic cholestasis). Reports of pregnancy in such patients are infrequent but, if pregnancy occurs, the underlying cholestasis may worsen [<a href="#rid61">61</a>]. (See  <a class="medical medical_review" href="/d/html/3584.html" rel="external">"Inherited disorders associated with conjugated hyperbilirubinemia", section on 'Alagille syndrome'</a> and  <a class="medical medical_review" href="/d/html/3584.html" rel="external">"Inherited disorders associated with conjugated hyperbilirubinemia", section on 'Progressive familial intrahepatic cholestasis'</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Porphyria</span><span class="headingEndMark"> — </span>These genetic disorders of heme metabolism can be exacerbated by estrogenic hormones and may cause maternal and fetal problems during pregnancy. Porphyria cutanea tarda, which is often associated with chronic hepatitis C, has rarely been reported to have its initial presentation during pregnancy [<a href="#rid62">62</a>]. (See  <a class="medical medical_review" href="/d/html/7101.html" rel="external">"Porphyrias: An overview"</a> and  <a class="medical medical_review" href="/d/html/3676.html" rel="external">"Extrahepatic manifestations of hepatitis C virus infection", section on 'Porphyria cutanea tarda'</a>.)</p><p>Recurrent attacks may occur during pregnancy in patients with acute intermittent porphyria, variegate porphyria, or hereditary coproporphyria and may be associated with intrauterine growth restriction or, rarely, maternal death [<a href="#rid63">63-65</a>]. </p><p>In a population-based study, women with the heritable form of porphyria cutanea tarda or with active acute porphyria during pregnancy had an excess risk of perinatal death (adjusted odds ratio [AOR] 4.9) [<a href="#rid65">65</a>]. Sporadic porphyria cutanea tarda was associated with an excess risk of small for gestational age (AOR 2.0), and for first-time mothers, low birth weight (AOR 3.4) and premature delivery (AOR 3.5).</p><p class="headingAnchor" id="H15"><span class="h2">Budd-Chiari syndrome</span><span class="headingEndMark"> — </span>Women with known Budd-Chiari syndrome (BCS) have become pregnant after the BCS has been treated and is well controlled. However, fetal outcomes remain relatively poor, possibly because of underlying prothrombotic disorders, and patients are counseled regarding fetal and maternal risk. In one study of 24 pregnancies, seven were lost prior to week 20, and there was one stillbirth [<a href="#rid66">66</a>]. In addition, two patients delivered between weeks 20 and 31, and 11 patients delivered between weeks 32 and 36. Finally, two patients developed symptomatic thrombotic complications. In another study including 80 women with BCS with &gt;8 year follow-up, 60 women (75 percent) conceived before symptom onset, and live birth rates were higher for women during treatment for BCS compared with prior to treatment (18 versus 0 percent) [<a href="#rid67">67</a>]. (See  <a class="medical medical_review" href="/d/html/93786.html" rel="external">"Budd-Chiari syndrome: Management"</a>.)</p><p>Treatment for BCS typically includes anticoagulation; however, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> is avoided during pregnancy. Thus, pregnant women are treated with low molecular weight heparin (LMWH) [<a href="#rid68">68</a>]. Multidisciplinary care is usually required for these patients, including the involvement of a hepatologist, hematologist, obstetrician, and maternal-fetal medicine specialist.</p><p class="headingAnchor" id="H4037130176"><span class="h2">Nonalcohol-associated fatty liver disease</span><span class="headingEndMark"> — </span>Nonalcohol-associated fatty liver disease (NAFLD) is characterized by hepatic steatosis in the absence of excessive alcohol use. In women of reproductive age, estimated NAFLD rates up to 18 percent have been reported [<a href="#rid69">69-71</a>]. However, rates may be much higher. In a cohort study using hospital discharge data, pregnancies impacted by NAFLD tripled from 2007 to 2015 [<a href="#rid72">72</a>]. Subsequent data from the United States National Health and Nutrition Examination Surveys (NHANES) found that 40 percent of the population between the ages of 15 and 39 had NAFLD as defined by vibration-controlled transient elastography (VCTE), and 20 percent of those with NAFLD had significant fibrosis (ie, F3 or greater) [<a href="#rid71">71</a>]. In a study using national administrative health care data, NAFLD was the most common etiology for cirrhosis during pregnancy (accounting for 72.5 percent of pregnancies with cirrhosis) [<a href="#rid73">73</a>]. The epidemiology and clinical features of NAFLD in the general population and the association of NAFLD with other disorders (eg, polycystic ovarian syndrome) are discussed separately [<a href="#rid74">74</a>]. (See  <a class="medical medical_review" href="/d/html/3625.html" rel="external">"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults"</a> and  <a class="medical medical_review" href="/d/html/7436.html" rel="external">"Clinical manifestations of polycystic ovary syndrome in adults"</a>.)</p><p>Data have suggested that gestational diabetes mellitus (GDM) is associated with NAFLD [<a href="#rid69">69,72,75</a>]. In a study including 608 pregnant women who had a liver ultrasound during the first trimester, women with hepatic steatosis had higher rates of GDM during the second trimester compared with women without steatosis (56 versus 16 percent) [<a href="#rid69">69</a>]. In addition, GDM was associated with development of NAFLD postpartum. In a large cohort study with 25 year follow-up, women with a history of GDM had higher rates of NAFLD compared with no GDM (14 versus 6 percent, OR 2.56, 95% CI: 1.44–4.55) [<a href="#rid72">72</a>]. (See  <a class="medical medical_review" href="/d/html/6790.html" rel="external">"Gestational diabetes mellitus: Glucose management and maternal prognosis"</a>.)</p><p>Specific outcomes include:</p><p class="bulletIndent1"><span class="glyph">●</span>Maternal outcome – Hepatic steatosis has been linked to several negative pregnancy outcomes, including preeclampsia and gestational hypertension [<a href="#rid76">76</a>]. Some studies have also found higher rates of caesarean section and preterm delivery (&lt;32 weeks) [<a href="#rid70">70,77</a>]. In addition, in a nationwide cohort study, maternal NAFLD was a risk factor for preeclampsia and GDM in mothers with a body mass index less than 30 kg/m<sup>2</sup> [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fetal outcomes – The impact of maternal steatosis on the infant is largely uncertain. However, in a study including 25 infants, neonatal intrahepatic fat (assessed by magnetic resonance imaging) was increased by 68 percent in the offspring of women with obesity and GDM compared with offspring of mothers without obesity [<a href="#rid78">78</a>]. Another study found that grade 2 to 3 steatosis by ultrasound in early pregnancy was a risk factor for large for gestational age (LGA) birth weight, even after adjusting for GDM [<a href="#rid79">79</a>]. </p><p></p><p class="headingAnchor" id="H16"><span class="h1">LIVER TRANSPLANTATION</span><span class="headingEndMark"> — </span>Patients who undergo orthotopic liver transplantation often regain their fertility [<a href="#rid80">80</a>]. Delaying conception until at least 24 months after transplantation is advised to allow for stabilization of the immunosuppressive regimen and to assure that the transplanted organ is functioning well [<a href="#rid81">81</a>]. Preconception care after liver transplantation is coordinated by clinicians from high-risk obstetrics and the liver transplant center. (See  <a class="medical medical_review" href="/d/html/448.html" rel="external">"The preconception office visit"</a>.)</p><p>Pregnancy outcomes for both the mother and infant in liver transplant recipients are generally good, but there is an increased incidence of preterm delivery, hypertension/preeclampsia, fetal growth restriction, and gestational diabetes [<a href="#rid81">81-90</a>]. The higher risk of preterm birth appears to be due in part to episodes of graft rejection and early onset preeclampsia [<a href="#rid81">81</a>]. Pregnancy-induced hypertension and preeclampsia may be related to an increased incidence of baseline renal dysfunction in these women and use of immunosuppressive therapy. The risk appears to be higher with use of <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> A than with <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>, but the number of reported patients is small [<a href="#rid81">81,91</a>]. Gestational diabetes is likely provoked by chronic <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> administration, thus these patients may benefit from diabetes screening in the first trimester, as well as between 24 and 28 weeks of gestation. (See  <a class="medical medical_review" href="/d/html/6797.html" rel="external">"Gestational diabetes mellitus: Screening, diagnosis, and prevention"</a>.)</p><p>Liver transplant patients require life-long immunosuppression. A slightly increased risk of teratogenicity has been suggested with standard immunosuppressive regimens that include glucocorticoids, <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>, and <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, but the magnitude of the risk is uncertain [<a href="#rid81">81,91</a>]. Increased monitoring of blood levels of <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> is needed because of increased hepatic clearance of cyclosporine during pregnancy [<a href="#rid92">92,93</a>]. <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">Mycophenolate</a> mofetil (MMF) use during pregnancy should be avoided as MMF has been associated with increased risk of fetal malformations and first-trimester pregnancy loss [<a href="#rid94">94,95</a>]. Pregnancies in women who have undergone liver transplantation should be managed together with a maternal-fetal medicine specialist. (See  <a class="medical medical_review" href="/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation"</a>.)</p><p>Although pregnancy does not increase the risk of maternal mortality in liver transplant recipients, these women should be aware of their prognosis for long-term survival and ability to care for a child. In one series of women who underwent liver transplantation from 1992 to 2002, 5 of 29 died between 10 and 54 months postpartum [<a href="#rid81">81</a>].</p><p>Both fetus and mother have survived liver transplantation performed during pregnancy [<a href="#rid92">92,96-99</a>]. Obviously, such heroic surgery must be considered with extreme care. If the condition prompting transplantation is caused by the pregnancy (eg, acute fatty liver of pregnancy), then prompt diagnosis followed by interruption of the pregnancy with maximal support of the mother is the treatment of choice. </p><p class="headingAnchor" id="H146896108"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cirrhosis and portal hypertension</strong> – Pregnancy has a variable effect in women with cirrhosis and portal hypertension. Worsening jaundice with progressive liver failure, ascites, and hepatic encephalopathy can occur, but some women with cirrhosis can sustain pregnancy without any worsening of hepatic function. In addition, the incidence of stillbirths and premature deliveries may be increased. (See <a class="local">'Cirrhosis and portal hypertension'</a> above.)</p><p></p><p class="bulletIndent1">The increase in total blood volume associated with pregnancy may worsen pre-existing portal hypertension. One approach to women with known cirrhosis who desire pregnancy is to perform an upper endoscopy to screen for varices before pregnancy (or during the second trimester if not performed prior to pregnancy). If present, patients should be informed of the increased risk of upper gastrointestinal hemorrhage with pregnancy. Patients at high risk for variceal hemorrhage should receive primary prophylaxis with nonselective beta blockers or endoscopic variceal ligation. Newborns whose mothers were receiving beta blockers should be monitored during the first days of life because of risks of hypoglycemia and bradycardia. (See <a class="local">'Assessing risk for variceal bleeding'</a> above.).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Viral hepatitis</strong> – Women chronically infected with hepatitis C virus (HCV) can have an uneventful pregnancy without worsening of liver disease or other adverse effects on the mother or fetus, although some studies have suggested potential harms. HCV is associated with an increased risk for intrahepatic cholestasis of pregnancy (ICP). Transmission of the virus from mother to the newborn occurs, but appears to be much less efficient than for hepatitis B virus infection. (See <a class="local">'Chronic hepatitis C virus'</a> above.)</p><p></p><p class="bulletIndent1">Pregnancy in women with chronic hepatitis B virus is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/83476.html" rel="external">"Hepatitis B and pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonalcohol-associated fatty liver disease (NAFLD)</strong> – Rates of NAFLD are increasing in females of childbearing age. NAFLD is now the leading cause for cirrhosis in the pregnant population. NAFLD during pregnancy increases the risk for complications including pregnancy-associated hypertensive disorders, gestational diabetes, and infants large for gestational age.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Liver transplant recipients</strong> – Patients who have undergone orthotopic liver transplantation often regain their fertility. Delaying conception until at least 24 months after transplantation is advised to allow for stabilization of the immunosuppressive regimen and to assure that the transplanted organ is functioning well. Pregnancy outcomes for both the mother and infant in liver transplant recipients are generally good, but there is an increased incidence of preterm delivery, hypertension/preeclampsia, fetal growth restriction, and gestational diabetes. In addition, there may be a slightly increased risk of teratogenicity with standard immunosuppressive regimens, but the magnitude of the risk is uncertain. (See <a class="local">'Liver transplantation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other liver conditions</strong> – Other liver diseases that may have an effect on or be affected by pregnancy include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Autoimmune hepatitis (see <a class="local">'Autoimmune hepatitis'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Primary biliary cholangitis (PBC) (see <a class="local">'Primary biliary cholangitis'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Primary sclerosing cholangitis (PSC) (see <a class="local">'Primary sclerosing cholangitis'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Wilson disease (see <a class="local">'Wilson disease'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Hepatocellular adenoma (HCA) (see <a class="local">'Hepatocellular adenoma'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Familial hyperbilirubinemia (see <a class="local">'Familial hyperbilirubinemia'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Familial intrahepatic cholestatic syndromes (Alagille syndrome and progressive familial intrahepatic cholestasis) (see <a class="local">'Familial intrahepatic cholestatic syndromes'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Porphyria (see <a class="local">'Porphyria'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Budd-Chiari syndrome (BCS) (see <a class="local">'Budd-Chiari syndrome'</a> above) </p><p></p><p><strong>ACKNOWLEDGMENT</strong> — The UpToDate editorial staff thank Yannick Bacq, MD, and Tram T Tran, MD, for their past contributions as authors to prior versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Varma RR. Course and prognosis of pregnancy in women with liver disease. Semin Liver Dis 1987; 7:59.</a></li><li><a class="nounderline abstract_t">Reau N, Munoz SJ, Schiano T. Liver Disease During Pregnancy. Am J Gastroenterol 2022; 117:44.</a></li><li><a class="nounderline abstract_t">Gawron LM, Sanders JN, Sward K, et al. Multi-morbidity and Highly Effective Contraception in Reproductive-Age Women in the US Intermountain West: a Retrospective Cohort Study. J Gen Intern Med 2020; 35:637.</a></li><li><a class="nounderline abstract_t">Westbrook RH, Yeoman AD, O'Grady JG, et al. Model for end-stage liver disease score predicts outcome in cirrhotic patients during pregnancy. Clin Gastroenterol Hepatol 2011; 9:694.</a></li><li><a class="nounderline abstract_t">Mass K, Quint EH, Punch MR, Merion RM. Gynecological and reproductive function after liver transplantation. Transplantation 1996; 62:476.</a></li><li><a class="nounderline abstract_t">Sarkar M, Brady CW, Fleckenstein J, et al. Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021; 73:318.</a></li><li><a class="nounderline abstract_t">Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.</a></li><li class="breakAll">Medical eligibility criteria for contraceptive use. Fifth edition. World Health Organization. August 2015. www.who.int/reproductivehealth/publications/family_planning/MEC-5/en/ (Accessed on May 23, 2019).</li><li class="breakAll">Mirena- levonorgestrel intrauterine device. US Food and Drug Administration (FDA) approved product information. Revised June, 2017. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on May 23, 2019).</li><li class="breakAll">Liletta- levonorgestrel intrauterine device. US Food and Drug Administration (FDA) approved product information. Revised July, 2018. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on May 23, 2019).</li><li class="breakAll">Kyleena- levonorgestrel intrauterine device. US Food and Drug Administration (FDA) approved product information. Revised March, 2018. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on May 23, 2019).</li><li class="breakAll">Skyla- levonorgestrel intrauterine device. US Food and Drug Administration (FDA) approved product information. Revised March, 2018. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on May 23, 2019).</li><li class="breakAll">Paragard T 380A- copper intrauterine device. US Food and Drug Administration (FDA) approved product information. Revised December, 2017. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on May 23, 2019).</li><li><a class="nounderline abstract_t">Kapp N, Tilley IB, Curtis KM. The effects of hormonal contraceptive use among women with viral hepatitis or cirrhosis of the liver: a systematic review. Contraception 2009; 80:381.</a></li><li><a class="nounderline abstract_t">Sinclair M, Schelleman A, Sandhu D, Angus PW. Regression of hepatocellular adenomas and systemic inflammatory syndrome after cessation of estrogen therapy. Hepatology 2017; 66:989.</a></li><li><a class="nounderline abstract_t">Flemming JA, Mullin M, Lu J, et al. Outcomes of Pregnant Women With Cirrhosis and Their Infants in a Population-Based Study. Gastroenterology 2020; 159:1752.</a></li><li><a class="nounderline abstract_t">Shaheen AA, Myers RP. The outcomes of pregnancy in patients with cirrhosis: a population-based study. Liver Int 2010; 30:275.</a></li><li><a class="nounderline abstract_t">Flemming JA, Dewit Y, Mah JM, et al. Incidence of cirrhosis in young birth cohorts in Canada from 1997 to 2016: a retrospective population-based study. Lancet Gastroenterol Hepatol 2019; 4:217.</a></li><li><a class="nounderline abstract_t">Doycheva I, Watt KD, Alkhouri N. Nonalcoholic fatty liver disease in adolescents and young adults: The next frontier in the epidemic. Hepatology 2017; 65:2100.</a></li><li><a class="nounderline abstract_t">Tan J, Surti B, Saab S. Pregnancy and cirrhosis. Liver Transpl 2008; 14:1081.</a></li><li><a class="nounderline abstract_t">Rasheed SM, Abdel Monem AM, Abd Ellah AH, Abdel Fattah MS. Prognosis and determinants of pregnancy outcome among patients with post-hepatitis liver cirrhosis. Int J Gynaecol Obstet 2013; 121:247.</a></li><li><a class="nounderline abstract_t">Westbrook RH, Dusheiko G, Williamson C. Pregnancy and liver disease. J Hepatol 2016; 64:933.</a></li><li><a class="nounderline abstract_t">Cheng YS. Pregnancy in liver cirrhosis and/or portal hypertension. Am J Obstet Gynecol 1977; 128:812.</a></li><li><a class="nounderline abstract_t">Schreyer P, Caspi E, El-Hindi JM, Eshchar J. Cirrhosis--pregnancy and delivery: a review. Obstet Gynecol Surv 1982; 37:304.</a></li><li><a class="nounderline abstract_t">Soto-Albors CE, Rayburn WF, Taylor L, Musselman M. Portal hypertension and hypersplenism in pregnancy secondary to chronic schistosomiasis. A case report. J Reprod Med 1984; 29:345.</a></li><li><a class="nounderline abstract_t">Britton RC. Pregnancy and esophageal varices. Am J Surg 1982; 143:421.</a></li><li><a class="nounderline abstract_t">Hillemanns P, Knitza R, Müller-Höcker J. Rupture of splenic artery aneurysm in a pregnant patient with portal hypertension. Am J Obstet Gynecol 1996; 174:1665.</a></li><li><a class="nounderline abstract_t">Tran TT, Ahn J, Reau NS. ACG Clinical Guideline: Liver Disease and Pregnancy. Am J Gastroenterol 2016; 111:176.</a></li><li><a class="nounderline abstract_t">Reiberger T, Ulbrich G, Ferlitsch A, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut 2013; 62:1634.</a></li><li><a class="nounderline abstract_t">Chandramouli S, Lee WM, Lo J, et al. Prophylactic Transjugular Intrahepatic Portosystemic Shunt Placement for Cirrhosis Management in Pregnancy. Hepatology 2020; 71:1876.</a></li><li><a class="nounderline abstract_t">Palatnik A, Rinella ME. Medical and Obstetric Complications Among Pregnant Women With Liver Cirrhosis. Obstet Gynecol 2017; 129:1118.</a></li><li><a class="nounderline abstract_t">Hagström H, Höijer J, Marschall HU, et al. Outcomes of Pregnancy in Mothers With Cirrhosis: A National Population-Based Cohort Study of 1.3 Million Pregnancies. Hepatol Commun 2018; 2:1299.</a></li><li class="breakAll">CDC National Profile of viral hepatitis. 2020. https://www.cdc.gov/hepatitis/statistics/2020surveillance/introduction/national-profile.htm (Accessed on December 17, 2022).</li><li><a class="nounderline abstract_t">Schillie S, Wester C, Osborne M, et al. CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020. MMWR Recomm Rep 2020; 69:1.</a></li><li class="breakAll">American College of Obstetricians and Gynecologists. Routine Hepatitis C Virus Screening in Pregnant Individuals. Available at https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2021/05/routine-hepatitis-c-virus-screening-in-pregnant-individuals (Accessed on December 18, 2022).</li><li class="breakAll">Society for Maternal Fetal Medicine. Available at https://www.smfm.org/publications/391-smfm-consult-series-56-hepatitis-c-in-pregnancyupdated-guidelines (Accessed on December 18, 2022).</li><li class="breakAll">U.S. Preventive Services Task Force. Hepatitis C Virus Infection in Adolescents and Adults: Screening. Available at https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/hepatitis-c-screening (Accessed on December 18, 2022).</li><li><a class="nounderline abstract_t">Carey I, Christiana M, Marie-Ange M, et al. Universal versus targeted screening for HCV infection in pregnancy in a diverse, multi-ethnic population: Universal screening is more comprehensive. J Viral Hepat 2022; 29:1079.</a></li><li><a class="nounderline abstract_t">Pergam SA, Wang CC, Gardella CM, et al. Pregnancy complications associated with hepatitis C: data from a 2003-2005 Washington state birth cohort. Am J Obstet Gynecol 2008; 199:38.e1.</a></li><li><a class="nounderline abstract_t">Kushner T, Djerboua M, Biondi MJ, et al. Influence of hepatitis C viral parameters on pregnancy complications and risk of mother-to-child transmission. J Hepatol 2022; 77:1256.</a></li><li><a class="nounderline abstract_t">Conte D, Fraquelli M, Prati D, et al. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology 2000; 31:751.</a></li><li><a class="nounderline abstract_t">Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today 1993; 14:353.</a></li><li><a class="nounderline abstract_t">Gervais A, Bacq Y, Bernuau J, et al. Decrease in serum ALT and increase in serum HCV RNA during pregnancy in women with chronic hepatitis C. J Hepatol 2000; 32:293.</a></li><li><a class="nounderline abstract_t">Fontaine H, Nalpas B, Carnot F, et al. Effect of pregnancy on chronic hepatitis C: a case-control study. Lancet 2000; 356:1328.</a></li><li><a class="nounderline abstract_t">Di Martino V, Lebray P, Myers RP, et al. Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology 2004; 40:1426.</a></li><li><a class="nounderline abstract_t">Benova L, Mohamoud YA, Calvert C, Abu-Raddad LJ. Vertical transmission of hepatitis C virus: systematic review and meta-analysis. Clin Infect Dis 2014; 59:765.</a></li><li><a class="nounderline abstract_t">Llovet LP, Horta D, Eliz MG, et al. Presentation and Outcomes of Pregnancy in Patients With Autoimmune Hepatitis. Clin Gastroenterol Hepatol 2019; 17:2819.</a></li><li><a class="nounderline abstract_t">Whelton MJ, Sherlock S. Pregnancy in patients with hepatic cirrhosis. Management and outcome. Lancet 1968; 2:995.</a></li><li><a class="nounderline abstract_t">Olsson R, Tysk C, Aldenborg F, Holm B. Prolonged postpartum course of intrahepatic cholestasis of pregnancy. Gastroenterology 1993; 105:267.</a></li><li><a class="nounderline abstract_t">Rabinovitz M, Appasamy R, Finkelstein S. Primary biliary cirrhosis diagnosed during pregnancy. Does it have a different outcome? Dig Dis Sci 1995; 40:571.</a></li><li><a class="nounderline abstract_t">Poupon R, Chrétien Y, Chazouillères O, Poupon RE. Pregnancy in women with ursodeoxycholic acid-treated primary biliary cirrhosis. J Hepatol 2005; 42:418.</a></li><li><a class="nounderline abstract_t">Lindor KD, Bowlus CL, Boyer J, et al. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology 2019; 69:394.</a></li><li><a class="nounderline abstract_t">Wellge BE, Sterneck M, Teufel A, et al. Pregnancy in primary sclerosing cholangitis. Gut 2011; 60:1117.</a></li><li><a class="nounderline abstract_t">Ludvigsson JF, Bergquist A, Ajne G, et al. A population-based cohort study of pregnancy outcomes among women with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2014; 12:95.</a></li><li><a class="nounderline abstract_t">Pfeiffenberger J, Beinhardt S, Gotthardt DN, et al. Pregnancy in Wilson's disease: Management and outcome. Hepatology 2018; 67:1261.</a></li><li><a class="nounderline abstract_t">Marrero JA, Ahn J, Rajender Reddy K, Americal College of Gastroenterology. ACG clinical guideline: the diagnosis and management of focal liver lesions. Am J Gastroenterol 2014; 109:1328.</a></li><li><a class="nounderline abstract_t">Wilson CH, Manas DM, French JJ. Laparoscopic liver resection for hepatic adenoma in pregnancy. J Clin Gastroenterol 2011; 45:828.</a></li><li><a class="nounderline abstract_t">Rifai K, Mix H, Krusche S, et al. No evidence of substantial growth progression or complications of large focal nodular hyperplasia during pregnancy. Scand J Gastroenterol 2013; 48:88.</a></li><li><a class="nounderline abstract_t">Friedlaender P, Osler M. Icterus and pregnancy. Am J Obstet Gynecol 1967; 97:894.</a></li><li><a class="nounderline abstract_t">Cohen L, Lewis C, Arias IM. Pregnancy, oral contraceptives, and chronic familial jaundice with predominantly conjugated hyperbilirubinemia (Dubin-Johnson syndrome). Gastroenterology 1972; 62:1182.</a></li><li><a class="nounderline abstract_t">Romero R, Reece EA, Riely C, Hobbins JC. Arteriohepatic dysplasia in pregnancy. Am J Obstet Gynecol 1983; 147:108.</a></li><li><a class="nounderline abstract_t">Rajka G. Pregnancy and porphyria cutanea tarda. Acta Derm Venereol 1984; 64:444.</a></li><li><a class="nounderline abstract_t">Brodie MJ, Moore MR, Thompson GG, et al. Pregnancy and the acute porphyrias. Br J Obstet Gynaecol 1977; 84:726.</a></li><li><a class="nounderline abstract_t">Kanaan C, Veille JC, Lakin M. Pregnancy and acute intermittent porphyria. Obstet Gynecol Surv 1989; 44:244.</a></li><li><a class="nounderline abstract_t">Tollånes MC, Aarsand AK, Sandberg S. Excess risk of adverse pregnancy outcomes in women with porphyria: a population-based cohort study. J Inherit Metab Dis 2011; 34:217.</a></li><li><a class="nounderline abstract_t">Rautou PE, Angermayr B, Garcia-Pagan JC, et al. Pregnancy in women with known and treated Budd-Chiari syndrome: maternal and fetal outcomes. J Hepatol 2009; 51:47.</a></li><li><a class="nounderline abstract_t">Shukla A, Sadalage A, Gupta D, et al. Pregnancy outcomes in women with Budd Chiari Syndrome before onset of symptoms and after treatment. Liver Int 2018; 38:754.</a></li><li><a class="nounderline abstract_t">European Association for the Study of the Liver. Electronic address: <span class="__cf_email__" data-cfemail="b8ddd9cbd4d7deded1dbddf8ddd9cbd4d7deded1dbdd96ddcd">[email protected]</span>. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol 2016; 64:179.</a></li><li><a class="nounderline abstract_t">Lee SM, Kwak SH, Koo JN, et al. Non-alcoholic fatty liver disease in the first trimester and subsequent development of gestational diabetes mellitus. Diabetologia 2019; 62:238.</a></li><li><a class="nounderline abstract_t">Herath RP, Siriwardana SR, Ekanayake CD, et al. Non-alcoholic fatty liver disease and pregnancy complications among Sri Lankan women: A cross sectional analytical study. PLoS One 2019; 14:e0215326.</a></li><li><a class="nounderline abstract_t">Alkhouri N, Almomani A, Le P, et al. The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database. BMC Gastroenterol 2022; 22:366.</a></li><li><a class="nounderline abstract_t">Ajmera VH, Gunderson EP, VanWagner LB, et al. Gestational Diabetes Mellitus Is Strongly Associated With Non-Alcoholic Fatty Liver Disease. Am J Gastroenterol 2016; 111:658.</a></li><li><a class="nounderline abstract_t">Sarkar M, Djerboua M, Flemming JA. NAFLD Cirrhosis Is Rising Among Childbearing Women and Is the Most Common Cause of Cirrhosis in Pregnancy. Clin Gastroenterol Hepatol 2022; 20:e315.</a></li><li><a class="nounderline abstract_t">Rocha ALL, Faria LC, Guimarães TCM, et al. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis. J Endocrinol Invest 2017; 40:1279.</a></li><li><a class="nounderline abstract_t">Mehmood S, Margolis M, Ye C, et al. Hepatic fat and glucose tolerance in women with recent gestational diabetes. BMJ Open Diabetes Res Care 2018; 6:e000549.</a></li><li><a class="nounderline abstract_t">Sarkar M, Grab J, Dodge JL, et al. Non-alcoholic fatty liver disease in pregnancy is associated with adverse maternal and perinatal outcomes. J Hepatol 2020; 73:516.</a></li><li><a class="nounderline abstract_t">Hagström H, Höijer J, Ludvigsson JF, et al. Adverse outcomes of pregnancy in women with non-alcoholic fatty liver disease. Liver Int 2016; 36:268.</a></li><li><a class="nounderline abstract_t">Brumbaugh DE, Tearse P, Cree-Green M, et al. Intrahepatic fat is increased in the neonatal offspring of obese women with gestational diabetes. J Pediatr 2013; 162:930.</a></li><li><a class="nounderline abstract_t">Lee SM, Kim BJ, Koo JN, et al. Nonalcoholic fatty liver disease is a risk factor for large-for-gestational-age birthweight. PLoS One 2019; 14:e0221400.</a></li><li><a class="nounderline abstract_t">Douglas NC, Shah M, Sauer MV. Fertility and reproductive disorders in female solid organ transplant recipients. Semin Perinatol 2007; 31:332.</a></li><li><a class="nounderline abstract_t">Nagy S, Bush MC, Berkowitz R, et al. Pregnancy outcome in liver transplant recipients. Obstet Gynecol 2003; 102:121.</a></li><li><a class="nounderline abstract_t">Radomski JS, Moritz MJ, Muñoz SJ, et al. National Transplantation Pregnancy Registry: analysis of pregnancy outcomes in female liver transplant recipients. Liver Transpl Surg 1995; 1:281.</a></li><li><a class="nounderline abstract_t">Armenti VT, Radomski JS, Moritz MJ, et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl 1997; :101.</a></li><li><a class="nounderline abstract_t">Patapis P, Irani S, Mirza DF, et al. Outcome of graft function and pregnancy following liver transplantation. Transplant Proc 1997; 29:1565.</a></li><li><a class="nounderline abstract_t">Scantlebury V, Gordon R, Tzakis A, et al. Childbearing after liver transplantation. Transplantation 1990; 49:317.</a></li><li><a class="nounderline abstract_t">Ville Y, Fernandez H, Samuel D, et al. Pregnancy in liver transplant recipients: course and outcome in 19 cases. Am J Obstet Gynecol 1993; 168:896.</a></li><li><a class="nounderline abstract_t">Rayes N, Neuhaus R, David M, et al. Pregnancies following liver transplantation--how safe are they? A report of 19 cases under cyclosporine A and tacrolimus. Clin Transplant 1998; 12:396.</a></li><li><a class="nounderline abstract_t">Wu A, Nashan B, Messner U, et al. Outcome of 22 successful pregnancies after liver transplantation. Clin Transplant 1998; 12:454.</a></li><li><a class="nounderline abstract_t">Raakow R, Neuhaus R, Büscher U, et al. Parenthood following liver transplantation. Transplant Proc 2001; 33:1450.</a></li><li><a class="nounderline abstract_t">Kubo S, Uemoto S, Furukawa H, et al. Pregnancy outcomes after living donor liver transplantation: results from a Japanese survey. Liver Transpl 2014; 20:576.</a></li><li><a class="nounderline abstract_t">Jain A, Venkataramanan R, Fung JJ, et al. Pregnancy after liver transplantation under tacrolimus. Transplantation 1997; 64:559.</a></li><li><a class="nounderline abstract_t">Roberts M, Brown AS, James OF, Davison JM. Interpretation of cyclosporin A levels in pregnancy following orthoptic liver transplantation. Br J Obstet Gynaecol 1995; 102:570.</a></li><li><a class="nounderline abstract_t">Keller F, Griesshammer M, Häussler U, et al. Pregnancy and renal failure: the case for application of dosage guidelines. Drugs 2001; 61:1901.</a></li><li><a class="nounderline abstract_t">Pisoni CN, D'Cruz DP. The safety of mycophenolate mofetil in pregnancy. Expert Opin Drug Saf 2008; 7:219.</a></li><li><a class="nounderline abstract_t">Society for Maternal-Fetal Medicine (SMFM), Irani RA, Coscia LA, et al. Society for Maternal-Fetal Medicine Consult Series #66: Prepregnancy evaluation and pregnancy management of patients with solid organ transplants. Am J Obstet Gynecol 2023; 229:B10.</a></li><li><a class="nounderline abstract_t">Laifer SA, Darby MJ, Scantlebury VP, et al. Pregnancy and liver transplantation. Obstet Gynecol 1990; 76:1083.</a></li><li><a class="nounderline abstract_t">Merritt WT, Dickstein R, Beattie C, et al. Liver transplantation during pregnancy: anesthesia for two procedures in the same patient with successful outcome of pregnancy. Transplant Proc 1991; 23:1996.</a></li><li><a class="nounderline abstract_t">Friedman E, Moses B, Engelberg S, et al. Malignant insulinoma with hepatic failure complicating pregnancy. South Med J 1988; 81:86.</a></li><li><a class="nounderline abstract_t">Kato T, Nery JR, Morcos JJ, et al. Successful living related liver transplantation in an adult with fulminant hepatic failure. Transplantation 1997; 64:415.</a></li></ol></div><div id="topicVersionRevision">Topic 3561 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3296216" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Course and prognosis of pregnancy in women with liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36194033" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Liver Disease During Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31701466" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Multi-morbidity and Highly Effective Contraception in Reproductive-Age Women in the US Intermountain West: a Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21570482" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Model for end-stage liver disease score predicts outcome in cirrhotic patients during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8781613" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Gynecological and reproductive function after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32946672" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19751861" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The effects of hormonal contraceptive use among women with viral hepatitis or cirrhosis of the liver: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28295483" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Regression of hepatocellular adenomas and systemic inflammatory syndrome after cessation of estrogen therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32781083" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Outcomes of Pregnant Women With Cirrhosis and Their Infants in a Population-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19874491" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The outcomes of pregnancy in patients with cirrhosis: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30573390" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Incidence of cirrhosis in young birth cohorts in Canada from 1997 to 2016: a retrospective population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28103626" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Nonalcoholic fatty liver disease in adolescents and young adults: The next frontier in the epidemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18668664" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pregnancy and cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23518137" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Prognosis and determinants of pregnancy outcome among patients with post-hepatitis liver cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26658682" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pregnancy and liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/327818" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pregnancy in liver cirrhosis and/or portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7048165" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Cirrhosis--pregnancy and delivery: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6726707" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Portal hypertension and hypersplenism in pregnancy secondary to chronic schistosomiasis. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6978619" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pregnancy and esophageal varices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9065156" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Rupture of splenic artery aneurysm in a pregnant patient with portal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26832651" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : ACG Clinical Guideline: Liver Disease and Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23250049" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31863592" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Prophylactic Transjugular Intrahepatic Portosystemic Shunt Placement for Cirrhosis Management in Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28486373" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Medical and Obstetric Complications Among Pregnant Women With Liver Cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30411076" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Outcomes of Pregnancy in Mothers With Cirrhosis: A National Population-Based Cohort Study of 1.3 Million Pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30411076" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Outcomes of Pregnancy in Mothers With Cirrhosis: A National Population-Based Cohort Study of 1.3 Million Pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32271723" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32271723" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32271723" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32271723" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36138559" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Universal versus targeted screening for HCV infection in pregnancy in a diverse, multi-ethnic population: Universal screening is more comprehensive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18486089" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pregnancy complications associated with hepatitis C: data from a 2003-2005 Washington state birth cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35643203" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Influence of hepatitis C viral parameters on pregnancy complications and risk of mother-to-child transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10706568" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8363725" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10707870" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Decrease in serum ALT and increase in serum HCV RNA during pregnancy in women with chronic hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11073028" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Effect of pregnancy on chronic hepatitis C: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15565616" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24928290" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Vertical transmission of hepatitis C virus: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30616023" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Presentation and Outcomes of Pregnancy in Patients With Autoimmune Hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4176376" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Pregnancy in patients with hepatic cirrhosis. Management and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8514043" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Prolonged postpartum course of intrahepatic cholestasis of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7895546" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Primary biliary cirrhosis diagnosed during pregnancy. Does it have a different outcome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15710226" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pregnancy in women with ursodeoxycholic acid-treated primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30070375" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21339205" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Pregnancy in primary sclerosing cholangitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23891928" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A population-based cohort study of pregnancy outcomes among women with primary sclerosing cholangitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28859232" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Pregnancy in Wilson's disease: Management and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25135008" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : ACG clinical guideline: the diagnosis and management of focal liver lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20962668" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Laparoscopic liver resection for hepatic adenoma in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23110461" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : No evidence of substantial growth progression or complications of large focal nodular hyperplasia during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6021104" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Icterus and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5050316" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Pregnancy, oral contraceptives, and chronic familial jaundice with predominantly conjugated hyperbilirubinemia (Dubin-Johnson syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6614078" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Arteriohepatic dysplasia in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6208730" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Pregnancy and porphyria cutanea tarda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/921907" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Pregnancy and the acute porphyrias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2652015" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Pregnancy and acute intermittent porphyria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20978938" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Excess risk of adverse pregnancy outcomes in women with porphyria: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19443069" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Pregnancy in women with known and treated Budd-Chiari syndrome: maternal and fetal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28834123" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Pregnancy outcomes in women with Budd Chiari Syndrome before onset of symptoms and after treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26516032" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : EASL Clinical Practice Guidelines: Vascular diseases of the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30470912" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Non-alcoholic fatty liver disease in the first trimester and subsequent development of gestational diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30978266" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Non-alcoholic fatty liver disease and pregnancy complications among Sri Lankan women: A cross sectional analytical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35907827" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27002796" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Gestational Diabetes Mellitus Is Strongly Associated With Non-Alcoholic Fatty Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33465483" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : NAFLD Cirrhosis Is Rising Among Childbearing Women and Is the Most Common Cause of Cirrhosis in Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28612285" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30233804" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Hepatic fat and glucose tolerance in women with recent gestational diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32531415" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Non-alcoholic fatty liver disease in pregnancy is associated with adverse maternal and perinatal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26114995" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Adverse outcomes of pregnancy in women with non-alcoholic fatty liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23260099" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Intrahepatic fat is increased in the neonatal offspring of obese women with gestational diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31449538" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Nonalcoholic fatty liver disease is a risk factor for large-for-gestational-age birthweight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18063116" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Fertility and reproductive disorders in female solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12850617" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Pregnancy outcome in liver transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9346583" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : National Transplantation Pregnancy Registry: analysis of pregnancy outcomes in female liver transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9919394" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9123426" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Outcome of graft function and pregnancy following liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2305462" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Childbearing after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8384405" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Pregnancy in liver transplant recipients: course and outcome in 19 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9787947" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Pregnancies following liver transplantation--how safe are they? A report of 19 cases under cyclosporine A and tacrolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9787957" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Outcome of 22 successful pregnancies after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11267369" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Parenthood following liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24478123" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Pregnancy outcomes after living donor liver transplantation: results from a Japanese survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9293865" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Pregnancy after liver transplantation under tacrolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7647064" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Interpretation of cyclosporin A levels in pregnancy following orthoptic liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11708763" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Pregnancy and renal failure: the case for application of dosage guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18462179" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : The safety of mycophenolate mofetil in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37088276" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Society for Maternal-Fetal Medicine Consult Series #66: Prepregnancy evaluation and pregnancy management of patients with solid organ transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2234717" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Pregnancy and liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2063469" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Liver transplantation during pregnancy: anesthesia for two procedures in the same patient with successful outcome of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2827322" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Malignant insulinoma with hepatic failure complicating pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9275105" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Successful living related liver transplantation in an adult with fulminant hepatic failure.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
